TV News LIES

Tuesday, Sep 30th

Last update06:05:20 AM GMT

You are here News Health Study outcome won't sway company on eye drug

Study outcome won't sway company on eye drug

E-mail Print PDF

What does a company do when there's anecdotal evidence that two of its drugs are equally effective in treating a leading cause of blindness in the elderly, one costing patients $60 per treatment and the other $2,000?

In the case of Genentech Inc., nothing.

The company declined to seek federal approval for the cheaper drug, Avastin, to treat the wet form of age-related macular degeneration. Nor would it help finance _ or cooperate with _ a National Eye Institute study comparing the effectiveness and safety of Avastin, a cancer drug, and the more expensive eye drug, Lucentis.

More...


Most Recent Related Stories...


Turmeric may ward off dementia, heal the brain

TurmericA new study by scientists in Germany has found a that a main ingredient in curry...

Ebola cases could reach between 550,000 and 1.4 million by late January: CDC

Ebola cases Between 550,000 and 1.4 million people in West Africa could be infected with the Ebola virus...

France to introduce plain cigarette packaging

French crackdown on smokingThe French government has unveiled controversial new measures to cut the number of its smokers, including...

Sierra Leone burial team attacked despite lockdown

Sierra Leone burial teamA team burying Ebola victims was attacked in Sierra Leone's capital on Saturday, a member of...
 
America's # 1 Enemy
Tee Shirt
& Help Support TvNewsLIES.org!
TVNL Tee Shirt
 
TVNL TOTE BAG
Conserve our Planet
& Help Support TvNewsLIES.org!
 
Get your 9/11 & Media
Deception Dollars
& Help Support TvNewsLIES.org!
 
The Loaded Deck
The First & the Best!
The Media & Bush Admin Exposed!